natgillin/translations-raw huggingface dataset:
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Riprazo HCT.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Riprazo HCT, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
It must not be taken with ciclosporin, itraconazole or other medicines known as ‘potent P-glycoprotein inhibitors' (such as quinidine).
Ne sme se jemati skupaj s ciklosporinom, itrakonazolom ali drugimi zdravili, znanimi kot „močni zaviralci Pglikoproteina“ (kot je kinidin).
By lowering blood pressure, the risk caused by high blood pressure, such as having a stroke, is reduced.
Z znižanjem krvnega tlaka se zmanjša tveganje, povezano z visokim krvnim tlakom, kot je kap.
Three additional studies were carried out to show that the active substances were absorbed in the body in the same way when they taken as separate tablets and as Riprazo HCT.
Izvedene so bile še tri dodatne študije, s katerimi je bilo dokazano, da se zdravilni učinkovini, ki se jemljeta v obliki ločenih tablet, absorbirata v telo enako kot zdravilo Riprazo HCT.
It works by increasing urine output, reducing the amount of fluid in the blood and reducing blood pressure.
Deluje tako, da poveča izločanje seča, zaradi česar se zmanjša količina tekočine v krvi in zniža krvni tlak.
Other information about Riprazo HCT
Druge informacije o zdravilu Riprazo HCT:
The studies compared the combination of aliskiren and hydrochlorothiazide with placebo (a dummy treatment), with aliskiren or hydrochlorothiazide taken alone, or with other medicines for hypertension (valsartan, irbesartan, lisinopril or amlodipine).
V študijah so primerjali kombinacijo aliskirena in hidroklorotiazida s placebom (zdravilom brez zdravilne učinkovine), aliskirenom ali hidroklorotiazidom kot samostojnima zdraviloma ali drugimi zdravili za zdravljenje hipertenzije (valsartanom, irbesartanom, lizinoprilom ali amlodipinom).
For the full list of all side effects reported with Riprazo HCT, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Riprazo HCT, glejte navodilo za uporabo.
Riprazo HCT must not be used in people who are hypersensitive (allergic) to aliskiren, hydrochlorothiazide, any of the other ingredients or sulfonamides.
Zdravila Riprazo HCT ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) aliskiren, hidroklorotiazid, katero koli drugo sestavino zdravila ali sulfonamide.
Riprazo HCT is used in patients whose blood pressure is not adequately controlled by aliskiren or hydrochlorothiazide taken alone.
Zdravilo Riprazo HCT se uporablja pri bolnikih, pri katerih krvni tlak ni ustrezno uravnan z jemanjem samo aliskirena ali hidroklorotiazida.
The company presented information used in the assessment of aliskiren and from the published literature to support its application for Riprazo HCT, as well as information from additional studies.
Družba je v podporo svoji vlogi za zdravilo Risprazo HCT predstavila informacije, ki so bile uporabljene pri oceni aliskirena, ter informacije iz objavljene literature in dodatnih študij.
It can also be used in patients whose blood pressure is adequately controlled with aliskiren and hydrochlorothiazide taken as separate tablets, to replace the same doses of the two active substances.
Lahko pa se uporablja tudi pri bolnikih, pri katerih je krvni tlak ustrezno uravnan z aliskirenom in hidroklorotiazidom, ki ju bolniki jemljejo kot ločeni tableti, kot nadomestitev istih odmerkov dveh zdravilnih učinkovin.
The combination of the two active substances has an additive effect, reducing the blood pressure more than either medicine alone.
Kombinacija obeh zdravilnih učinkovin daje boljše rezultate pri zniževanju krvnega tlaka kot vsako posamezno zdravilo posebej.
Patients previously taking only aliskiren or hydrochlorothiazide may need to take the two substances as separate tablets and adjust the doses before switching to Riprazo HCT.
Bolniki, ki so predhodno jemali samo aliskiren ali hidroklorotiazid, bodo morda morali vzeti obe učinkovini v ločenih tabletah in odmerke pred prehodom na zdravilo Riprazo HCT prilagoditi.
In patients whose blood pressure was not adequately controlled on either aliskiren or hydrochlorothiazide alone, switching to the combination resulted in greater falls in blood pressure than remaining on one active substance alone.
Pri bolnikih, pri katerih krvni tlak ni bil ustrezno uravnan samo z jemanjem aliskirena ali hidroklorotiazida, je prehod na kombinacijo zdravil povzročil večji padec krvnega tlaka kot jemanje samo ene zdravilne učinkovine.
It must not be used in patients who have had angioedema (swelling under the skin) with aliskiren, hereditary angioedema or angioedema of no obvious cause, who have severe kidney or liver impairment, or whose blood potassium levels are too low or blood calcium levels are too high.
Ne sme se uporabljati pri bolnikih, pri katerih se je zaradi jemanja aliskirena pojavil angioedem (podkožno otekanje), pri bolnikih z dednim angioedemom ali angioedemom brez jasnega vzroka, pri bolnikih s hudo jetrno oziroma ledvično okvaro ali pri bolnikih, ki imajo prenizke ravni kalija oziroma previsoke ravni kalcija.
Riprazo HCT in combination with an ‘angiotensin converting enzyme (ACE) inhibitors' or ‘angiotensin receptor blockers' (ARBs) must not be used in patients with diabetes, or moderate or severe kidney impairment.
Zdravilo Riprazo HCT se v kombinaciji z zaviralcem angiotenzinske konvertaze ali zaviralcem angiotenzinskih receptorjev ne sme uporabljati pri bolnikih s sladkorno boleznijo oziroma zmerno ali hudo okvaro ledvic.
In patients already adequately controlled with the two active substances, the dose of Riprazo HCT must contain the same doses of aliskiren and hydrochlorothiazide that the patient was taking before.
Pri bolnikih, pri katerih je krvni tlak že uravnan z obema zdravilnima učinkovinama, mora odmerek zdravila Riprazo HCT vsebovati enak odmerek aliskirena in hidroklorotiazida, kot ju je bolnik jemal prej.
What is the risk associated with Riprazo HCT?
Kakšna tveganja so povezana z zdravilom Riprazo HCT?
Riprazo HCT is a medicine that contains the active substances aliskiren and hydrochlorothiazide.
Riprazo HCT je zdravilo, ki vsebuje zdravilni učinkovini aliskiren in hidroklorotiazid.
Why has Riprazo HCT been approved?
Zakaj je bilo zdravilo Riprazo HCT odobreno?
It blocks the activity of a human enzyme called renin, which is involved in the production of a substance called angiotensin I in the body.
Zavira dejavnost človeškega encima, imenovanega renin, ki v telesu sodeluje pri tvorjenju snovi, imenovane angiotenzin I. Angiotenzin I se pretvori v hormon angiotenzin II, ki deluje kot močan vazokonstriktor (učinkovina, ki oži žile).
Riprazo HCT contains two active substances, aliskiren and hydrochlorothiazide.
Zdravilo Riprazo HCT vsebuje dve zdravilni učinkovini, aliskiren in hidroklorotiazid.
How has Riprazo HCT been studied?
Kako je bilo zdravilo Riprazo HCT raziskano?
What is Riprazo HCT?
Kaj je zdravilo Riprazo HCT?
What is Riprazo HCT used for?
Za kaj se zdravilo Riprazo HCT uporablja?
How is Riprazo HCT used?
Kako se zdravilo Riprazo HCT uporablja?
How does Riprazo HCT work?
Kako zdravilo Riprazo HCT deluje?
Repeat this action vigorously for at least 15 seconds.
Postopek odločno ponavljajte vsaj 15 sekund.
Vaccination is the best way to protect against these diseases.
Cepljenje je najboljši način zaščite proti tema boleznima.
Most people recover completely but the illness is usually severe enough to keep people ill for about a month.
Večina ljudi popolnoma okreva, toda bolezen je običajno tako huda, da so bolniki bolni približno mesec dni.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 20 September 1996
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum prve odobritve: 20. september 1996
Date of latest renewal: 28 August 2006
Datum zadnjega podaljšanja: 28. avgust 2006
Hold the syringe upright in a closed hand.
Brizgo držite pokončno v zaprti dlani.
1 month later
1 mesec pozneje
7 days later
7 dni pozneje
• you have a severe infection with a high temperature (over 38°C).
• imate hujšo okužbo z visoko telesno temperaturo (višjo od 38 ˚C).
Such reactions may occur before leaving the doctor's surgery.
Take reakcije se lahko zgodijo, preden zapustite ambulanto.
at an elected date
na izbrani dan
- neomycin.
- neomicin.
Young children may not develop jaundice.
Majhni otroci včasih ne razvijejo zlatenice.
The vaccine should never be given into a vein.
Cepiva se nikoli ne sme dajati v žilo.
The vaccine may contain traces of neomycin which is used during the manufacturing process (see section 4.3).
Cepivo lahko vsebuje sledi neomicina, ki se uporablja v proizvodnem procesu (glej poglavje 4.3).
Protection against hepatitis A and hepatitis B develops within 2-4 weeks.
Zaščita pred virusom hepatitisa A in hepatitisa B se razvije v 2-4 tednih.
- Primary vaccination schedule
- Osnovna shema cepljenja
• you have a poor immune system due to illness or drug treatment.
• imate oslabel imunski sistem zaradi bolezni ali jemanja zdravil.
Do not use this medicine after the expiry date which is stated on the carton.
Tega cepiva ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli.
The first dose will be given on an elected date.
Prvi odmerek boste prejeli na izbrani dan.
b. If the vaccine still does not appear as a uniform hazy white suspension - tip upside down and back again for at least another 15 seconds - then inspect again.
b. če cepivo še vedno ni videti kot enotna, motno bela suspenzija - brizgo ponovno prevračajte na glavo in spet nazaj za vsaj nadaljnjih 15 sekund - nato ponovno preglejte cepivo.
Symptoms of hepatitis A begin 3 to 6 weeks after coming into contact with the virus.
Simptomi hepatitisa A se običajno pojavijo 3 do 6 tednov po stiku z virusom.
Shake the syringe by tipping it upside down and back again.
Brizgo pretresite tako, da jo prevračate na glavo in spet nazaj.
This schedule may be given to adults only needing a rapid protection (e.g. overseas travellers).
To shemo cepljenja se lahko uporablja samo pri odraslih, ki potrebujejo hitro zaščito (npr. pri popotnikih).
• you have experienced any health problems after previous administration of a vaccine.
• ste po predhodnem cepljenju imeli kakršne koli zdravstvene težave.
The vaccine has not been tested in patients with impaired immunity.
Cepivo ni bilo preizkušeno pri bolnikih z oslabljeno imunostjo.
21 days after the first dose
21 dni po prvem odmerku
None of the components in the vaccine are infectious.
Nobena od sestavin tega cepiva ni kužna.
If you are pregnant or breast-feeding, think that you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before you are given this vaccine.
Nosečnost in dojenje Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom ali farmacevtom, preden prejmete to cepivo.
You will receive a total of three injections over 6 months.
Skupaj boste prejeli tri injekcije cepiva v 6 mesecih.
Guidelines for boosting are based on the assumption that antibodies are required for protection; anti-HAV antibodies have been predicted to persist for at least 10 years.
Smernice za poživitveno cepljenje temeljijo na predpostavki, da so za zaščito nujno potrebna protitelesa; anti-HAV protitelesa naj bi se po ocenah ohranila najmanj 10 let.
Hypersensitivity to the active substances or to any of the excipients listed in section 6.1 or neomycin.
Preobčutljivost na zdravilni učinkovini ali katero koli pomožno snov, navedeno v poglavju 6.1, ali neomicin.
After a few days the whites of eyes and skin may become yellowish (jaundice).
Po nekaj dneh lahko koža in/ali beločnice postanejo rumenkaste barve (zlatenica).
Pack sizes of 1, 10 and 25 with or without needles.
Velikosti pakiranja: 1, 10 ali 25 z iglami ali brez njih.
• A temporary inflammation of the nerves, causing pain, weakness and paralysis in the extremities and often progressing to the chest and face (Guillain-Barré syndrome)
• začasno vnetje živcev, ki povzročajo bolečino, šibkost in paralizo v ekstremitetah in često napredujejo proti prsnemu košu in obrazu (Guillain-Barré-jev sindrom),
A minor infection such as a cold should not be a problem, but talk to your doctor first.
Blažja okužba, na primer prehlad, ne predstavlja ovire, toda pred cepljenjem se o tem kljub temu pogovorite s svojim zdravnikom.
Pharmaco-therapeutic group: Hepatitis vaccines, ATC code: J07BC20.
Farmakoterapevtska skupina: Cepiva proti hepatitisu, oznaka ATC: J07BC20
However, if you get any of these symptoms you should contact a doctor urgently.
Če se vam pojavijo kateri koli od teh simptomov, morate nujno poklicati zdravnika.
• Infection around the brain which may give severe headache with stiff neck and sensitivity to light (meningitis)
• okužba okrog možganov, ki lahko povzroči hud glavobol z otrdelim vratom in občutljivostjo na svetlobo (meningitis),
After a fourth dose given at month 12, the incidence of systemic and local adverse reactions was comparable to that seen after vaccination at 0, 7, 21 days.
Po četrtem odmerku prejetem v 12. mesecu, je pojavnost sistemskih in lokalnih neželenih reakcij primerljiva s tisto po cepljenju na 0, 7, 21 dan.
• Reduction in blood platelets, which increases risk of bleeding or bruising
• znižanje števila krvnih ploščic (trombocitov), ki zviša tveganje za krvavitev ali pojav modric
PARTICULARS TO APPEAR ON THE OUTER PACKAGING 1 PRE-FILLED SYRINGE WITHOUT NEEDLE 10 PRE-FILLED SYRINGES WITHOUT NEEDLE 25 PRE-FILLED SYRINGES WITHOUT NEEDLE 1 PRE-FILLED SYRINGE WITH 1 NEEDLE 10 PRE-FILLED SYRINGES WITH 10 NEEDLES 25 PRE-FILLED SYRINGES WITH 25 NEEDLES
PODATKI NA ZUNANJI OVOJNINI 1 NAPOLNJENA INJEKCIJSKA BRIZGA BREZ IGLE 10 NAPOLNJENIH INJEKCIJSKIH BRIZG BREZ IGEL 25 NAPOLNJENIH INJEKCIJSKIH BRIZG BREZ IGEL 1 NAPOLNJENA INJEKCIJSKA BRIZGA Z 1 IGLO 10 NAPOLNJENIH INJEKCIJSKIH BRIZG Z 10 IGLAMI 25 NAPOLNJENIH INJEKCIJSKIH BRIZG Z 25 IGLAMI
General guidelines for booster vaccination can therefore be drawn from experience with the monovalent vaccines.
Splošne napotke za poživitvena cepljenja se zato lahko povzame iz izkušenj z monovalentnimi cepivi.
The kinetics of antibody decline are also similar.
Tudi upadanje titra protiteles je podobno.
The vaccine should not be given (deep) into the skin or intramuscularly into the buttock because protection may be less.
Cepiva se ne sme injicirati (globoko) v kožo ali intramuskularno v zadnjico, saj je pri takšnem načinu dajanja zaščita lahko manjša.
One month after the fourth dose, all vaccinees demonstrated seroprotective levels of anti-HBs antibodies and were seropositive for anti-HAV antibodies.
En mesec po četrtem odmerku so imele vse cepljene osebe zaščitni nivo anti-HBs protiteles in so bile seropozitivne na anti-HAV protitelesa.
This study did not indicate direct or indirect harmful effects with respect to fertility, pregnancy, embryonal/fetal development, parturition or post-natal development.
Ta študija ni pokazala neposrednih ali posrednih škodljivih vplivov na plodnost, brejost, razvoj zarodka/plodu, porod ali postnatalni razvoj.
The remaining 2 doses will be given 7 days and 21 days after the first dose.
Preostala dva odmerka boste prejeli sedem in enaindvajset dni po prvem odmerku.
The HA virus is propagated in MRC5 human diploid cells.
HA virus je namnožen na humanih diploidnih celicah MRC5.
The remaining two doses will be given one month, and six months after the first dose.
Preostala dva odmerka boste prejeli en mesec in šest mesecev po prvem odmerku.
Your doctor may advise you to have a blood test after you have completed the course of vaccinations to check if you have made a satisfactory response.
Vaš zdravnik vam lahko svetuje, da po prejemu vseh predvidenih odmerkov cepiva opravite krvne preiskave, da bi tako ugotovil, če je odziv na cepljenje zadovoljiv.
It may be expected that in patients receiving immunosuppressive treatment or patients with immunodeficiency, an adequate response may not be achieved.
Pričakujemo lahko, da pri osebah, ki prejemajo imunosupresivno zdravljenje, ali bolnikih z imunsko pomanjkljivostjo morda ne bo dosežen ustrezen imunski odgovor.
• you have previously had an allergic reaction to any vaccine against hepatitis A and hepatitis B diseases.
• ste kdaj imeli alergijsko reakcijo na katero koli drugo cepivo proti hepatitisu A ali hepatitisu B.
The vaccine should be re-suspended following the steps below.
Cepivo je treba pretresti upoštevajoč naslednje korake:
Subjects received an additional dose of the same vaccine(s) 48 months after the first dose of the primary vaccination course.
Osebe so dobile dodaten odmerek enakega cepiva/enakih cepiv 48 mesecev po prvem odmerku primarnega cepljenja.
Side effects that may occur are the following:
Možni neželeni učinki so:
• Hepatitis A: Hepatitis A is an infectious disease, which can affect the liver.
• Hepatitis A: Hepatitis A je nalezljiva bolezen, ki prizadene jetra.
Long-term antibody persistence data following vaccination with Twinrix Adult are available up to 15 years after vaccination.
Na voljo so podatki o dolgotrajni prisotnosti protiteles po cepljenju s cepivom Twinrix za odrasle v trajanju do 15 let po cepljenju.
The vaccine will not prevent infection caused by other agents such as hepatitis C and hepatitis E and other pathogens known to infect the liver.
Cepivo ne bo preprečilo okužbe z drugimi povzročitelji, kot sta virus hepatitisa C in hepatitisa E, ali drugimi patogeni, ki lahko prizadenejo jetra.
If you miss a scheduled injection, talk to your doctor and arrange another visit.
Če ste izpustili odmerek ob dogovorjenem času, se pogovorite z zdravnikom in se dogovorite za naslednji obisk.
6 months after the first dose
12 mesecev po prvem odmerku
Anti-HBs antibody concentrations decreased as age and body mass index increased; they were also lower in male than in female subjects.
Koncentracije protiteles anti-HB so bile manjše tudi zaradi višje starosti in indeksa telesne mase, bile pa so sicer nižje pri moških kot pri ženskah.
Frequencies are reported as: Very common: ≥ 1/10 Common:
Pogostnost je navedena kot: Zelo pogosti:
The vaccine should be inspected visually for any foreign particulate matter and/or abnormal physical appearance prior to administration.
Pred uporabo je treba cepivo vizualno pregledati glede morebitnih tujih delcev in/ali nenormalnega fizikalnega videza.
EU/1/96/020/001 - pack of 1 without needle EU/1/96/020/002 - pack of 10 without needle EU/1/96/020/003 - pack of 25 without needle EU/1/96/020/007 - pack of 1 with 1 needle EU/1/96/020/008 - pack of 10 with 10 needles EU/1/96/020/009 - pack of 25 with 25 needles
EU/1/96/020/001 - 1 napolnjena injekcijska brizga brez igle EU/1/96/020/002 - 10 napolnjenih injekcijskih brizg brez igle EU/1/96/020/003 - 25 napolnjenih injekcijskih brizg brez igle EU/1/96/020/007 - 1 napolnjena injekcijska brizga z 1 iglo EU/1/96/020/008 - 10 napolnjenih injekcijskih brizg z 10 iglami EU/1/96/020/009 - 25 napolnjenih injekcijskih brizg z 25 iglami
Hepatitis B surface antigen3,4
Površinski antigen virusa hepatitisa B3,4
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.
Zahteve glede predložitve redno posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7)
• Swelling of the face, mouth or throat (angioneurotic oedema)
• oteklina obraza, ust ali grla (angionevrotični edem),
The hepatitis A virus can be passed from person to person in food and drink, or by swimming in water contaminated by sewage.
To bolezen povzroča virus hepatitisa A. Virus hepatitisa A se lahko z osebe na osebo prenaša s hrano in pijačo ali s plavanjem v vodi, onesnaženi s fekalijami.
6.6 Special precautions for disposal and other handling Upon storage, a fine white deposit with a clear colourless layer above may be observed.
6.6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom Med shranjevanjem se lahko pojavi fina bela usedlina in bister brezbarvni zgornji sloj.
A decision on whether to continue/discontinue breastfeeding or to continue/discontinue therapy with Twinrix Adult should be made taking into account the benefit of breast-feeding to the child and the benefit of Twinrix Adult therapy to the woman.
Pri odločanju o nadaljevanju/prekinitvi dojenja ali nadaljevanju/prekinitvi cepljenja s cepivom Twinrix za odrasle je treba upoštevati tako korist dojenja za otroka kot korist cepljenja s cepivom Twinrix za odrasle za mater.
The seroprotection rate against hepatitis B increased to 95.1% by three months after the first dose.
Stopnja zaščite proti hepatitisu B je porasla na 95,1 % v treh mesecih po prvem odmerku.
Twinrix Adult is available in packs of 1, 10, and 25 with or without needles.
Cepivo Twinrix za odrasle je na voljo v pakiranjih po 1, 10 in 25 z iglami ali brez njih.
Twinrix Adult is a vaccine used in adults and adolescents 16 years of age and above to prevent two diseases: hepatitis A and hepatitis B. The vaccine works by causing the body to produce its own protection (antibodies) against these diseases.
Twinrix za odrasle je cepivo, ki se uporablja pri odraslih in mladostnikih, starih 16 let in več, za preprečevanje dveh bolezni: hepatitisa A in hepatitisa B. Cepivo deluje tako, da spodbudi telo k proizvajanju lastne zaščite (protiteles) proti tema boleznima.
Specific humoral antibodies against hepatitis B were observed in 70% of the adults after the first dose and approximately 99% after the third dose.
Specifična humoralna protitelesa proti hepatitisu B so ugotovili pri 70 % odraslih po prvem odmerku in pri približno 99 % po tretjem odmerku.
While it is not expected that recombinant hepatitis B virus surface antigen would have adverse effects on pregnancies or the fetus it is recommended that vaccination should be delayed until after delivery unless there is an urgent need to protect the mother against hepatitis B infection.
Škodljivega vpliva rekombinantnega površinskega antigena virusa hepatitisa B na nosečnost ali plod sicer ne pričakujemo, vendar kljub temu priporočamo, da se cepljenje odloži na čas po porodu, če matere ni treba nujno zaščititi pred okužbo z virusom hepatitisa B.
Encephalitis, encephalopathy, neuritis, neuropathy, paralysis, convulsions
Bolezni živčevja encefalitis, encefalopatija, nevritis, nevropatija, paraliza, konvulzije
Data on outcomes of a limited number of pregnancies in vaccinated women do not indicate any adverse effects of Twinrix Adult on pregnancy or on the health of the fetus/newborn child.
Podatki o izidih nosečnosti, pridobljeni pri manjšem številu cepljenih nosečnic, ne kažejo na možnost škodljivih vplivov cepiva Twinrix za odrasle na nosečnost ali zdravje plodu/novorojenca.
Upon storage, a fine white deposit with a clear colourless layer above may be observed.
Med shranjevanjem se lahko pojavi fina bela usedlina in bister brezbarvni zgornji sloj.
• Degenerative disease of the brain (encephalopathy)
• degenerativna bolezen možganov (encefalopatija),
• Inflammation of some blood vessels (vasculitis)
• okužba nekaterih krvnih žil (vaskulitis),
The kinetics of decline of anti-HAV and anti-HBs antibodies were shown to be similar to those of the monovalent vaccines.
Kinetika upadanja nivoja anti-HAV in anti-HBs protiteles je bila podobna kot pri monovalentnih cepivih.